• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Bill Ackman Sees U-Turn at Valeant, Pershing Square's Biggest Flop so Far

The billionaire activist has no shortage of investment blunders, but shareholders can learn a lot from his biggest flop to date.
By JAMES PASSERI Mar 30, 2016 | 12:47 PM EDT
Stocks quotes in this article: VRX, HLF, JCP

Billionaire activist Bill Ackman has had no shortage of self-proclaimed "worst" investments in the 12-year history of his hedge fund, Pershing Square.

In 2012, it was his 40% stake in flagging bookseller Borders. Then there were Ackman's 2014 laments over losses in J.C. Penney (JCP). Finally, last year saw dismal reports of his botched campaign to bring down Herbalife (HLF). 

But as far as Ackman's flops go, Valeant Pharmaceuticals (VRX) really stands alone.

The beleaguered Canadian drugmaker thrashed Pershing Square and its 9% stake last year with a negative 20.5% return net of fees. And 2016 doesn't appear any better, with shares down 72% year to date as of Wednesday morning trading.

But aside from the steep, and unprecedented, troubles that Valeant wreaked on Pershing last year, the investment is also unique for Ackman in the sense that there is so far literally no way to properly account for the damages: By Valeant's own admission, its last several filings with the Securities and Exchange Commission should be considered null and void due to bookkeeping misconduct.

The $58 million in sales Valeant improperly booked for 2014 tied to its partnership with mail-order pharmacy Philador could have a spillover effect on other quarters and retroactively on 2015, the company said in a March SEC filing. And the oversight has contributed to ongoing investigations by the SEC and Congress.

And the murky bookkeeping surrounding Valeant has also delayed the filing of its annual 10-K. And kicking the can down the road for much longer could trigger covenant breaches on Valeant's debt -- one of the few accounting metrics shareholder's have a clear view on.

The $30.88 billion in debt that Valeant booked in the third quarter last year is nearly twice the $16.27 accounted for year over year. Meanwhile, the $526.8 million of net income filed with the SEC over Valeant's trailing four quarters is down from $947.5 million in all of 2014.

But the key to an overhaul, Ackman said last week in a letter to Valeant investors, will be reversing the negative media scrutiny the drugmaker seems incapable of shaking off.

Controversy surrounding Valeant's accounting and drug pricing most recently came to a head with the Senate issuing a subpoena to outgoing CEO Michael Pearson, who is set to testify about Valeant's drug pricing practices next month. And the company's pricing practices have also has been highlighted by the campaign of Democratic presidential candidate Hillary Clinton, who has alleged that Valeant is guilty of "gouging" patients with "predatory pricing."

"One of the greatest threats to the company's performance is the morale issues created by a collapsing stock price, constant attacks in the media, and the inherent uncertainty of the events of the last few months," said Ackman, who has newfound clout in the company given the ouster of Pearson and the recent appointment of Ackman and Pershing vice-chairman Steve Fraidin to Valeant's board. 

"While trust and confidence can vaporize quickly, it also can be restored rapidly when appropriate governance, oversight, and management issues are addressed properly," he added. "We believe that when the 10-K is filed, new leadership is identified, and the market understands that Valeant has adopted a new approach to communicating with the public, investor confidence will be restored and the stock should trade at a price which better reflects its business fundamentals."

Prior to Ackman's engagement with Valeant, his former investment misadventures included the bankruptcy of Borders, a 40% equity stake of which Ackman began winding down in 2011 after booking about a $200 million loss, according to the Wall Street Journal. And the market cap of J.C. Penney has roughly halved since Ackman began buying shares of the apparel retailer in earnest in the fall of 2010. Meanwhile, shares of the nutrition products distributor Herbalife have climbed more than 125% since Ackman launched his short posiiton in December 2012, despite multiple Pershing presentations alleging Herbalife's central business model resembles a Ponzi scheme.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

It's an Opportune Time to Renew Your Vows With CVS Health

Paul Price
Feb 18, 2021 7:00 AM EST

The pharmacy giant offered a great buy/write options play last summer and is setting up again for such action.

Just Had My First Teladoc Appointment: Is the Rally Over?

Bruce Kamich
Feb 17, 2021 2:39 PM EST

I may be late to trends, but not to stock charts.

CVS Health Reports Q4, and Here's What I'm Changing Up

Stephen Guilfoyle
Feb 16, 2021 10:55 AM EST

I do want to give new CEO Karen Lynch a chance. Nothing against Larry Merlo but I always thought that this stock was undervalued.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login